

FOR IMMEDIATE RELEASE

Contact: John Hawkins
Executive Vice President
MedPointe Inc.
(732) 564-2233
jhawkins@medpointepharma.com
www.medpointepharma.com

**MEDPOINTE AND SEPRACOR AGREE
TO PHASE OUT ASTELIN[®] CO-PROMOTION**

*MedPointe's Enlarged Sales Force, Sepracor's Pending Estorra[™] Approval
Drive Decision to Sunset Collaboration*

Somerset, NJ – April 30, 2004 – MedPointe and Sepracor Inc. today announced that they have amended their agreement for the co-promotion of MedPointe's ASTELIN[®] (azelastine HCl). Sepracor will continue to detail ASTELIN this spring and will receive compensation consistent with the terms of their agreement until June 30, 2004. As of July 1, 2004, Sepracor will only be responsible for providing sample coverage for ASTELIN under a fee-based compensation program through the duration of the amended agreement. The amendment also creates accelerated termination rights for each party, which if exercised, would result in a one-time residual payment to Sepracor in recognition of Sepracor's contribution to building brand awareness of ASTELIN.

Paul Edick, President of MedPointe, commented, "We have appreciated the assistance that Sepracor has given MedPointe in promoting ASTELIN and believe this amendment, which phases out our co-promotion agreement, is in the interest of both parties. Since we signed the original deal with Sepracor in August 2002, MedPointe has added three new sales forces, comprised of 260 new sales representatives, increasing our total to 560 field sales representatives. Of these three new field forces, one is a Specialty Allergy field force. Along with our strong Primary Care field presence, we

are ready to resume full responsibility for the promotion of our ASTELIN brand. We wish Sepracor well in its launch of ESTORRA and the commercialization of its other brands.”

“ASTELIN has been a good strategic fit for our sales force, which has also detailed Sepracor’s own respiratory product, XOPENEX[®], a nebulized beta-agonist,” said W. James O’Shea, President and Chief Operating Officer at Sepracor. “However, with the anticipated launch of ESTORRA[™] (eszopiclone) for the treatment of insomnia, we are focusing our efforts on our own proprietary products.”

Sepracor Inc. (NASDAQ: SEPR) is a research-based pharmaceutical company dedicated to treating and preventing human disease through the discovery, development and commercialization of innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor’s corporate headquarters are located in Marlborough, Massachusetts. For more information on Sepracor, visit www.sepracor.com.

MedPointe Inc. is a privately held specialty pharmaceutical company located at 265 Davidson Avenue, Suite 300, Somerset, New Jersey, 08873-4120; 732-564-2200. Backed by private equity investors, including The Carlyle Group and The Cypress Group, MedPointe specializes in respiratory, allergy, central nervous system, and pediatric products. The Company maintains a manufacturing facility in Decatur, IL. For more information on MedPointe, visit www.medpointepharma.com.

Astelina is a registered trademark of MedPointe Inc. Estorra is a trademark and Xopenex is a registered trademark of Sepracor Inc.